The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1-23.[4] Podar K, Leleu X. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers (Basel). 2021;13(20):5154.[5] ECIS - European Cancer ...
Multiple myeloma is cancer of plasma cells, which are white blood cells that reside in the bone marrow. Multiple myeloma typically begins as monoclonal gammopathy of undetermined significance (MGUS), which is a precancerous condition in which asymptomatic people have an antibody or pieces of...
Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)Introduction: Chimeric antigen receptor T-cell (CAR-T) products have shown an impressive response in relapsed/refractory MM patients (pts). The pivotal KarMMa-3 (Otero-Rodriguez P et al, ...
Multiple Myeloma: Impact of Time to Transplant on the Outcome 2022, Clinical Lymphoma, Myeloma and Leukemia Citation Excerpt : 85.1% of patients had adequate CD 34 + stem cells (≥2 × 106/Kg) collection in the early transplant compared to 81.5% in the late transplant cohort (P = .180)...
(Statistics developed by the National Cancer Institute) than if under the care of one of these exceptional myeloma professionals or under the care of a doctor considered to be a myeloma specialist. An explanation of the math is provided at the end of this home page. You will also find a ...
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell...
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. Br J Haematol. 2022;199:190–204. 19. O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, et al. A phase 2 study of modified lenalidomide, ...
Multiple myeloma represents about 1% of all cancers and 10–20% of all hematologic malignancies. The clonal proliferation of malignant plasma cells in the bone marrow may result both in local growth and in systemic effects due to the overproduction of a monoclonal protein (M-protein). Plasma cel...
There is an urgent need to provide equitable care for multiple myeloma and CLL patients and reduce the emotional and financial consequences of the disease for the patient. A survey about diagnosis and therapeutic resources was conducted between April and May 2023 among large centers in the Public,...
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma Andrea Keppler-Hafkemeyer, Christine Greil, Paul R. Wratil, Khalid Shoumariyeh, Marcel Stern, Annika Hafkemeyer, Driti Ashok, Alexandra ...